Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis.
In a series of 5 patients with early post-transplant FSGS recurrence resistant to plasma exchange and rituximab, combined rituximab plus daratumumab induced a complete response in all cases and was well tolerated.
Category
Transplant
Source
Am J Transplant
Excerpt
1. Am J Transplant. 2024 Apr;24(4):688-692. doi: 10.1016/j.ajt.2023.12.010. Epub 2023 Dec 14. Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis. Angeletti A(1), Bin S(2), Magnasco A(3), Bruschi M(3), Cravedi P(2), Ghiggeri GM(3). Author information: (1)Nephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. Electronic address: [email protected]. (2)Translational Transplant Research Center and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. (3)Nephrology, Dialysis and Transplantation Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. Focal segmental glomerulosclerosis (FSGS) is one of the leading causes of kidney failure and it is
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.